Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

  1. Citrome, L.
  2. Sánchez del Rio, M.
  3. Dong, Y.
  4. Nichols, R.M.
  5. Tockhorn-Heidenreich, A.
  6. Foster, S.A.
  7. Stauffer, V.L.
Journal:
Advances in Therapy

ISSN: 1865-8652,  0741-238X

Year of publication: 2021

Volume: 38

Issue: 8

Pages: 4442-4460

Type: Article

DOI: 10.1007/S12325-021-01848-X GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus